GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Larimar Therapeutics Inc (STU:ZA71) » Definitions » Dividend-Payout-to-FFO

Larimar Therapeutics (STU:ZA71) Dividend-Payout-to-FFO


View and export this data going back to 2020. Start your Free Trial

What is Larimar Therapeutics Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Larimar Therapeutics Business Description

Traded in Other Exchanges
Address
Three Bala Plaza East, Suite 506, Bala Cynwyd, PA, USA, 19004
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.